Sucampo Pharmaceuticals (NASDAQ: SCMP) has recently received a number of price target changes and ratings updates:

  • 10/17/2017 – Sucampo Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $11.00 price target on the stock. According to Zacks, “Sucampo is focused on expanding Amitiza’s label and penetrating new markets. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Also, through the agreement with Cancer Prevention Pharmaceuticals, Sucampo acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, dependence of Sucampo on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. A decline in Amitiza's sales will adversely impact the top line. Moreover, it had its share of pipeline setbacks. Shares of the company have underperformed the industry. Estimates have remained stable ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in the recent quarters.”
  • 10/12/2017 – Sucampo Pharmaceuticals had its price target lowered by analysts at UBS AG from $19.00 to $15.00. They now have a “buy” rating on the stock.
  • 10/3/2017 – Sucampo Pharmaceuticals was downgraded by analysts at Mizuho from a “buy” rating to a “neutral” rating. They now have a $12.00 price target on the stock, down previously from $14.00.
  • 10/3/2017 – Sucampo Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Sucampo is focused on expanding Amitiza’s label and penetrating into new markets. Also, the company’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Also, through the agreement with Cancer Prevention Pharmaceuticals, the company acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning. Also, some companies are trying to market and sell generic version of Amitiza. A decline in Amitiza's sales will adversely impact the top line. Moreover, it had its share of pipeline setbacks. The company has lowered its earnings outlook to include the Vtesee acquisition. Shares of the company have underperformed the industry.”
  • 8/21/2017 – Sucampo Pharmaceuticals is now covered by analysts at Leerink Swann. They set an “outperform” rating and a $15.00 price target on the stock.

Sucampo Pharmaceuticals, Inc. (NASDAQ SCMP) traded up 0.245% on Thursday, reaching $10.225. 147,524 shares of the company traded hands. The stock’s market capitalization is $473.67 million. The firm has a 50 day moving average price of $11.50 and a 200 day moving average price of $10.69. Sucampo Pharmaceuticals, Inc. has a 52-week low of $9.30 and a 52-week high of $17.55.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.06. The business had revenue of $59.90 million for the quarter, compared to analyst estimates of $56.44 million. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. Sucampo Pharmaceuticals’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.24 EPS. Equities research analysts predict that Sucampo Pharmaceuticals, Inc. will post $1.01 EPS for the current year.

In other news, insider Jason Patrick Meyenburg acquired 4,000 shares of Sucampo Pharmaceuticals stock in a transaction that occurred on Wednesday, September 6th. The shares were acquired at an average price of $12.13 per share, for a total transaction of $48,520.00. Following the transaction, the insider now directly owns 30,228 shares of the company’s stock, valued at approximately $366,665.64. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The disclosure for this sale can be found here. Insiders own 4.13% of the company’s stock.

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Receive News & Ratings for Sucampo Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.